Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D D Whang

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Invasive Cardiology|April 14, 2000
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?D A Tramuta, D J Kereiakes, E J Dippel, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 14, 2001
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous managementE J Dippel, D J Kereiakes, D A Tramuta, et al.
American Heart Journal|September 30, 2000
Abciximab provides cost-effective survival advantage in high-volume interventional practiceD J Kereiakes, R L Obenchain, B L Barber, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Invasive Cardiology|April 14, 2000
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?D A Tramuta, D J Kereiakes, E J Dippel, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 14, 2001
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous managementE J Dippel, D J Kereiakes, D A Tramuta, et al.
American Heart Journal|September 30, 2000
Abciximab provides cost-effective survival advantage in high-volume interventional practiceD J Kereiakes, R L Obenchain, B L Barber, et al.
Pageof 2